CINECA IRIS Institutional Research Information System

FALLAHI, POUPAK
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.663
AS - Asia 8.231
EU - Europa 7.242
SA - Sud America 1.840
AF - Africa 297
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 12
Totale 39.303
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.156
IT - Italia 3.014
CN - Cina 2.611
HK - Hong Kong 1.852
SG - Singapore 1.839
BR - Brasile 1.575
SE - Svezia 1.198
BG - Bulgaria 710
VN - Vietnam 691
DE - Germania 575
RU - Federazione Russa 398
CA - Canada 387
TR - Turchia 366
GB - Regno Unito 348
FI - Finlandia 265
IN - India 182
UA - Ucraina 180
FR - Francia 114
KR - Corea 106
AR - Argentina 99
IQ - Iraq 96
NL - Olanda 92
BD - Bangladesh 86
CI - Costa d'Avorio 84
JP - Giappone 72
MX - Messico 56
AT - Austria 49
PL - Polonia 48
CH - Svizzera 46
EC - Ecuador 42
ID - Indonesia 42
BE - Belgio 38
PK - Pakistan 38
ZA - Sudafrica 38
SN - Senegal 36
SA - Arabia Saudita 35
ES - Italia 34
CO - Colombia 31
NG - Nigeria 30
PY - Paraguay 28
UZ - Uzbekistan 28
MA - Marocco 27
VE - Venezuela 23
CZ - Repubblica Ceca 22
IE - Irlanda 20
KE - Kenya 18
TN - Tunisia 18
AE - Emirati Arabi Uniti 17
LT - Lituania 17
UY - Uruguay 16
AU - Australia 15
EG - Egitto 15
IR - Iran 15
IL - Israele 14
JO - Giordania 14
NP - Nepal 14
PH - Filippine 14
RO - Romania 12
OM - Oman 11
PE - Perù 11
BJ - Benin 10
GR - Grecia 10
JM - Giamaica 10
MY - Malesia 10
DO - Repubblica Dominicana 9
KZ - Kazakistan 9
PT - Portogallo 9
CL - Cile 8
TT - Trinidad e Tobago 8
TW - Taiwan 8
GT - Guatemala 7
LB - Libano 7
RS - Serbia 7
AL - Albania 6
AZ - Azerbaigian 6
BH - Bahrain 6
DZ - Algeria 6
EU - Europa 6
HU - Ungheria 6
BO - Bolivia 5
GE - Georgia 5
HN - Honduras 5
KW - Kuwait 5
NI - Nicaragua 5
PA - Panama 5
AM - Armenia 4
BY - Bielorussia 4
EE - Estonia 4
PS - Palestinian Territory 4
QA - Qatar 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
BN - Brunei Darussalam 3
CU - Cuba 3
DK - Danimarca 3
ET - Etiopia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
ML - Mali 3
NO - Norvegia 3
Totale 39.257
Salva come PNG Salva come JPEG
Città #
Fairfield 2.489
Ashburn 2.259
Woodbridge 2.051
Hong Kong 1.840
Houston 1.384
Dallas 1.373
Chandler 1.180
Ann Arbor 1.165
Santa Clara 1.087
Seattle 1.076
Serra 989
Singapore 893
Wilmington 864
Cambridge 862
Sofia 709
Shanghai 692
Milan 615
Beijing 593
New York 466
Boardman 355
Princeton 343
Ottawa 313
Pisa 292
Lawrence 286
Medford 264
Los Angeles 260
Nanjing 194
Jacksonville 184
Izmir 181
Des Moines 179
Dong Ket 174
Hefei 153
Munich 151
Istanbul 131
São Paulo 130
Redondo Beach 125
San Diego 124
Florence 118
Buffalo 117
London 116
Ho Chi Minh City 108
Rome 104
Seoul 102
Columbus 100
The Dalles 94
Frankfurt am Main 88
Dearborn 87
Abidjan 84
Boulder 65
Tokyo 65
Nanchang 62
Hanoi 55
Ogden 55
Rio de Janeiro 54
Kunming 51
Changsha 48
Council Bluffs 48
Redwood City 47
Bremen 45
Chicago 44
Turku 44
Shenyang 43
Falls Church 42
Hebei 41
Fuzhou 40
Norwalk 40
Belo Horizonte 37
Brussels 37
Dakar 36
Nuremberg 35
Bern 34
Phoenix 32
Jüchen 31
Warsaw 30
Tianjin 29
Vienna 29
Washington 29
Pune 28
Tashkent 28
Baghdad 27
San Francisco 27
Jiaxing 26
Lagos 26
Brasília 25
Dhaka 25
Rho 25
Guangzhou 24
Hyderabad 24
Düsseldorf 23
Sulaymaniyah 23
Toronto 23
Amsterdam 22
Curitiba 22
Johannesburg 22
Porto Alegre 22
Zhengzhou 22
Brooklyn 21
Quanzhou 20
Salvador 20
Indiana 19
Totale 29.336
Salva come PNG Salva come JPEG
Nome #
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 323
Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. 236
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 220
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 216
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 208
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. 206
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 206
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 205
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 203
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia 202
Molecular testing in the diagnosis of differentiated thyroid carcinomas 195
Autoimmune thyroid disorders 193
B-cells and mixed cryoglobulinemia. 192
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 192
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 191
Sorafenib in the treatment of thyroid cancer 191
Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts. 190
3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats 189
Aggressive thyroid cancer: targeted therapy with sorafenib 189
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 189
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts 188
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 185
Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. 184
HCV-related autoimmune and neoplastic disorders: the HCV syndrome 183
Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. 182
Sunitinib in the treatment of thyroid cancer 181
Sorafenib and Thyroid Cancer 179
Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10 178
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 178
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 172
Body composition and cardiac dimensions in elite rhythmic gymnasts 170
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone 169
Selective use of vandetanib in the treatment of thyroid cancer 169
Novel therapies for thyroid autoimmune diseases: An update 167
Cytokines and HCV-Related Disorders. 166
Putative biomarkers for malignant pleural mesothelioma suggested by proteomic analysis of cell line secretome 166
L’esperienza della Medicina del Lavoro della Azienda Ospedaliero-Universitaria Pisana nella sorveglianza sanitaria degli ex-esposti ad amianto, alla luce delle linee di indirizzo della regione Toscana 165
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition 165
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 165
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 164
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ 164
TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation 163
CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer 163
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 163
Evaluation of the Anti-Spike (RDB) IgG Titer among Workers Employed at the University of Pisa Vaccinated with Different Types of SARS-CoV-2 Vaccines 162
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine 162
Biomarkers in the prevention and follow-up of workers exposed to asbestos 162
Analysis of chromosome damage in circulating lymphocytes of radiological workers affected by thyroid nodules 161
Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients 161
Cabozantinib in Thyroid Cancer 161
Analysis of survival at cardiac arrest in events occurred in work environments in the territory served by an operations center of the 118 of Tuscany 160
CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes 159
New insight in endocrine-related adverse events associated to immune checkpoint blockade 159
New targeted molecular therapies for dedifferentiated thyroid cancer. 158
Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident 158
Cytokines and HCV-related autoimmune disorders 157
Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature 157
Thyroid disorders induced by checkpoint inhibitors 157
Thyroid cancer in HCV-related mixed cryoglobulinemia patients. 156
RET TKI: Potential Role in Thyroid Cancers 156
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 156
Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study 156
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests 154
High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C 153
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. 152
Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied 152
Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy 151
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection 150
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 150
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 150
The Endocrinology of Liver Disease. 149
The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients 149
Stem cells: their role in breast cancer development and resistance to treatment. 148
New targeted therapies for anaplastic thyroid cancer. 147
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 147
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. 146
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 146
The association of Sjögren syndrome and autoimmune thyroid disorders 146
Endocrine Manifestations of HCV-Positive Cryoglobulinemia 146
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up 146
Changes in autonomic regulation and ventricular repolarization induced by subclinical hyperthyroidism 145
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy 145
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 145
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 144
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 144
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 144
Novel treatments for anaplastic thyroid carcinoma 143
Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. 142
Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia 142
The emerging extrahepatic manifestations oh hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. 141
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. 141
Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer 141
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy 140
High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. 140
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review 139
Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. 139
Big and Free Fractions of Gamma-Glutamyltransferase: New Diagnostic Biomarkers for Malignant Mesothelioma? 139
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 138
Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer 138
Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis 138
Totale 16.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.841 0 0 0 0 182 98 83 361 172 322 143 480
2021/20223.378 70 154 119 214 554 460 97 223 171 145 228 943
2022/20233.428 502 409 225 306 373 504 58 249 498 15 242 47
2023/20242.900 290 325 359 228 426 521 144 107 47 54 100 299
2024/20259.613 203 372 132 586 885 1.130 778 545 884 1.217 1.009 1.872
2025/20265.318 861 1.379 1.586 992 500 0 0 0 0 0 0 0
Totale 40.447